Global industries face immense pressure to enhance public health and safety amidst rising antimicrobial resistance and complex supply chains. Regulatory bodies worldwide are tightening standards for pathogen detection in healthcare, food production, and water management, driving demand for advanced, real-time monitoring solutions. Companies that can rapidly identify and respond to microbial threats will gain a significant competitive edge, minimizing recall risks, protecting brand reputation, and optimizing operational efficiencies across their value chains.
Reduces evaluation time by ~90% compared to conventional culture methods, enabling results in minutes to hours.
Enables high-precision individual microbial evaluation, detecting subtle susceptibility changes missed by bulk methods.
Automates and streamlines inspection processes, replacing complex manual culture and visual observation with electrical signal analysis.
This patent, with 8 claims, comprehensively covers the entire process from individual microbial separation and electrical treatment to current response measurement and susceptibility determination/display. Its novelty and inventiveness have been objectively proven through examination against multiple prior art documents, ensuring strong and stable protection against future invalidation challenges. This provides licensees with broad technical protection, enabling confident development and deployment of products and services.
This patent focuses on the measurement device and method. White space exists in developing novel electrical disinfection protocols or integrating this rapid testing capability into fully autonomous microbial control systems for specific industrial or medical environments.
Annual costs for microbial susceptibility testing in medical institutions and food factories are estimated at ~$1.2M (AI est.), including personnel costs for 5 technicians (~$200K/person/year (AI est.)) and conventional culture/waste disposal expenses. Implementing this technology is projected to reduce personnel costs by 20% and reagent/waste disposal costs by 30% due to faster testing. This results in an estimated annual cost reduction of ~$1.0M (AI est.) (calculated as ~$1.2M × 0.85).
X: Speed & Real-time Capability
Y: Accuracy & Automation Efficiency